Skip to main content
Equibles
ELVN logo

ELVN · Enliven Therapeutics, Inc. · Metrics

Track ELVN — free

Use ELVN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ELVN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$41.52 -0.41 (-0.98%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$3.04B
Shares
73.27M
Volume · Oct 23 2.3M Avg daily vol (3M) 1.27M

ELVN metrics

62 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$41.52
Market cap
$3.04B

Price action

20 metrics
Price change (1W)
+11.3%
Price change (30D)
-7.2%
Price change (3M)
-21.6%
Price change (6M)
-6.2%
Price change (YTD)
+169.6%
Price change (1Y)
+102.0%
Trailing year
Price change (5Y)
+190.8%
52-week high
$61.15
52-week low
$15.14
Change from 52-week high
-32.1%
Change from 52-week low
+174.2%
Annualized volatility
79.3%
Annualized volatility (3M)
40.9%
Beta
1.1
RSI (14D)
39.9
Price vs SMA 50
-17.4%
Price vs SMA 200
-1.8%
Avg volume (3M)
1.27M
Relative volume
1.8
Average dollar volume
$64.20M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
73.27M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.4
reciprocal yield 29.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-3.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-27

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$124.41M
Net income (TTM)
−$105.93M
Trailing 12 months
Diluted EPS (TTM)
$-1.64
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.96
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.67
Operating cash flow per diluted share (TTM)
$-1.06
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.40
Stock compensation per diluted share (TTM)
$0.64
Book value per share
$7.73

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+27.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-11.8%
Return on assets
-11.6%
Debt / equity
—
Current ratio
64.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
64.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$895.15M
Latest balance sheet
Cash & equivalents
$135.50M
Total assets
$910.22M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$66.94M
Capital expenditures (TTM)
$98,000
R&D (TTM)
$89.15M
SG&A (TTM)
—
Stock compensation (TTM)
$40.81M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
215
13F filer change QoQ
+41
Institutional ownership
109.9%
Conviction holders (share of 13F filers)
6.1%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+30.3%
Holder tenure
8.4
Price vs estimated holder cost
+80.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
9.6%

Short interest

3 metrics
Short interest
14.1%
Latest settlement · 5.5 days to cover
Days to cover
5.5d
Short-squeeze score
86 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$11.79M
Insider-sentiment score
40 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1672619 CUSIP 29337E102 13F (30d) 14 filings 14 filers Visit website Investor relations